High Purity Raws Clioquinol CAS 130-26-7 for Topical Antifungal Treatment

High Purity Raws Clioquinol CAS 130-26-7 for Topical Antifungal Treatment

Product Name: Clioquinol
Synonyms: 5-Chlor-7-jod-8-hydroxy-chinolin;5-chloro-7-iodo-8-quinolino;7-Iodo-5-chloroxine;8-Quinolinol, 5-chloro-7-iodo-;ala-quin;Alchloquin;alchoquin;alioform
CAS: 130-26-7
MF: C9H5ClINO
MW: 305.5
EINECS: 204-984-4

Clioquinol Usage And Synthesis

Usage alpha adrenergic blocker, mydriatic, antidepressant
Usage Used as a topical antifungal treatment
General Description Cream-colored to brownish-yellow powder. Practically odorless. Decomposes at 178-179°C. Used as a topical anti-infective.
Air & Water Reactions Insoluble in water.
Reactivity Profile Clioquinol is incompatible with strong oxidizing agents, strong acids, acid chlorides and acid anhydrides . Darkens on exposure to light.
Fire Hazard Flash point data for Clioquinol are not available; however, Clioquinol is probably combustible.

Clioquinol Antiprotozoal use

A 1964 report described the use of Clioquinol in both the treatment and prevention of shigella infection and Entamoeba histolytica infection in institutionalized individuals at Sonoma State Hospital in California. The report indicates 4000 individuals were treated over a 4-year period with few side effects.[3]

Several recently reported journal articles describing its use as an antiprotozoal include:

A 2005 reference to its use in treating a Dutch family for Entamoeba histolytica infection.[4]
A 2004 reference to its use in the Netherlands in the treatment of Dientamoeba fragilis infection.[5]
A 1979 reference to the use in Zaire in the treatment of Entamoeba histolytica infection.

Clioquinol Topical use

Clioquinol is a constituent of the prescription medicine Vioform, which is a topical antifungal treatment. It is also used in the form of a cream (and in combination with betamethasone) in the treatment of inflammatory skin disorders.

Use in neurodegenerative diseases

Research at UCSF indicates that clioquinol appears to block the genetic action of Huntington's disease in mice and in cell culture.[11]

Evidence from phase 2 clinical trials suggested that clioquinol could halt cognitive decline in Alzheimer's disease, possibly owing to its ability to act as a chelator for copper and zinc ions. This led to development of analogs including PBT2 as potential therapeutic compounds for the treatment of Alzheimer's disease.[12]

Recent animal studies have shown that clioquinol can reverse the progression of Alzheimer's, Parkinson's and Huntington's diseases. According to Dr. Siegfried Hekimi and colleagues at McGill's Department of Biology, clioquinol acts directly on a protein called Clk-1, often informally called “clock-1,” and might slow down the aging process. They theorize that this may explain the apparent ability of the drug to be effective in the above conditions, but warn against individuals experimenting with this drug.